Drug Regulatory Authority of Pakistan (DRAP) has issued a clarification letter on SRO 1688 following consultations with the Nutraceutical Manufacturers Association of Pakistan (NMAP) to address regulatory ambiguities and concerns raised by the industry.
DRAP clarifies SRO 1688 on industry concerns
ISLAMABAD, Nov 02 (APP):Drug Regulatory Authority of Pakistan (DRAP) has issued a clarification letter on SRO 1688 following consultations with the Nutraceutical Manufacturers Association of Pakistan (NMAP) to address regulatory ambiguities and concerns raised by the industry.
In a statement, NMAP Founder Chairman Muhammad Danish Khan said the association had maintained continuous coordination with DRAP’s senior leadership to seek clarification on the matter and resolve issues affecting nutraceutical manufacturers.
Representing around 450 nutraceutical manufacturers across Pakistan, the association appreciated DRAP Chief Executive Officer Dr. Obaidullah Malik for considering the industry’s concerns and facilitating their resolution.
Danish Khan also acknowledged the efforts of Director Health and OTC Ajmal Sohail Asif, who held multiple meetings with NMAP and worked to address the industry’s reservations and regulatory uncertainties.
He also appreciated the Special Investment Facilitation Council (SIFC) for its support and facilitation in addressing challenges faced by Pakistan’s nutraceutical industry.
The NMAP chairman said the association remained committed to promoting the growth and development of the sector and would continue cooperating with DRAP, SIFC and other relevant government institutions to resolve industry-related issues.
He expressed confidence that continued collaboration between the government and industry stakeholders would help create a more enabling regulatory environment, promote sustainable growth and strengthen Pakistan’s nutraceutical sector.
